United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

A lot of money could ride on a planned second version of Pfizer's coronavirus vaccine.

Pfizer's Next Multibillion-Dollar COVID Vaccine Move

Amgen

Teladoc

If you're worried about another market crash, don't pass up these three unstoppable healthcare stocks.

3 No-Brainer Stocks to Buy in Healthcare

The company sounded alarm bells about the widening gap between the initial shot and booster of BNT162b2.

Pfizer Criticizes Sudden Change in Coronavirus Vaccine Dosing Regime in the U.K.

PFE stock does not include any value to the Pfizer-BioNTech partnership and the developments of a game-changing Covid-19 vaccine. The post Why Pfizer is the Cheapest Coronavirus Vaccine Play appeared first on InvestorPlace.

Why Pfizer is the Cheapest Coronavirus Vaccine Play

The U.K. National Health Service has pushed back the window for people to receive the second dose of the coronavirus vaccine made by Pfizer and BioNTech — to a duration the companies tested on only a small percentage of patients.

U.K. health service pushes back interval for delivering second Pfizer coronavirus vaccine to a duration company says is untested

With Pfizer delivering Covid-19 vaccines, PFE stock appears to be the pandemic's winner. However, a new strain of SARS-CoV-2 and fresh competition may apply some pressure.

Why the New Covid-19 Strain Matters for Pfizer Stakeholders

Abbott Labs

Costco

These companies are heavyweights, and they're only getting stronger.

The 3 Safest Stocks to Buy With Your Stimulus Money

The EU's total order now stands at 300 million.

Pfizer and BioNTech Supplying 100 Million Additional Doses of Coronavirus Vaccine to European Union

AbbVie

Bristol-Myers

Johnson & Johnson

AbbVie and Bristol-Myers Squibb are major pharmaceuticals that have recently made large acquisitions that have significantly increased their total debt. However, both AbbVie and Bristol-Myers Squibb have robust drug pipelines and are actively expanding indications of key therapeutics to drive strong growth going forward.

Undervalued Pharmaceutical Dividends For The New Year

European Commission President Ursula von der Leyen took to Twitter to announce Tuesday that the European Union will purchase an additional 100 million doses of the Pfizer (NYSE: PFE)-BioNTech (NASDAQ: BNTX) coronavirus vaccine.  We decided to take an additional 100 million doses of the #BioNTech /@Pfizer vaccine, which is already being used to vaccinate people across the EU.

European Union Set To Purchase 100M More Doses Of Pfizer COVID-19 Vaccine

Pfizer Inc. and its German partner BioNTech SE will supply an additional 100 million doses of their COVID-19 vaccine to the 27 member states of the European Union, the companies said in a joint statement. The move comes after the European Commission exercised an option to purchase the extra doses that was granted as part of an agreement signed in November.

Pfizer and BioNTech to supply additional 100 million COVID vaccine doses to EU in 2021

Myovant Sciences

Myovant Sciences (MYOV) and Pfizer enter collaboration agreement to develop and commercialize relugolix monotherapy and combination regimen for prostate cancer and uterine fibroids, respectively.

Myovant (MYOV) Up on Collaboration With Pfizer for Relugolix

PFE stock has had 2 recent mega rallies and it could have another one. But it's best asset is the support below and the dividend yield.

Pfizer Stock Is Too Hot but It's Definitely Safe to Handle Here

Pfizer's (PFE) label expansion application for Lorbrena as first-line treatment for metastatic lung cancer gets priority review from the FDA.

Pfizer (PFE) Lorbrena First-Line sNDA Gets FDA Priority Review

Disney

D.R. Horton

Pfizer (NYSE:PFE), Walt Disney (NYSE:DIS) and D.R. Horton (NYSE:DHI) are among my favorite stocks for the coming year.

My Favorite Stocks for 2021: Pfizer, Disney, 8 Others

Shopify

A new year comes with new opportunities and challenges for investors looking to make a smart bet. Here are the top stocks set for huge returns in 2021.

3 Stocks Set for Huge Returns In 2021

Moderna

Mutations could mean more money for the two drugmakers.

Why New Coronavirus Strains Could Boost Pfizer and Moderna's Fortunes

For all the hoopla, PFE stock has already seen the benefit of the Covid-19 vaccine and needs new catalysts. Still, long-term investors may want it's healthy dividend.

Pfizer's All-in Costs Show Vaccine Probably Won't Move the Needle Much

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for LORBRENA ® (lorlatinib) as a first-line treatment for people with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). The sNDA is based on data from the pivotal CROWN study and is being reviewed by the FDA under its Real-Time Oncology Review (RTOR) pilot program. T

LORBRENA® (lorlatinib) sNDA in Previously Untreated ALK-Positive Lung Cancer Accepted for Priority Review by U.S. FDA

Shares of Myovant surged as much as 35% to $30 on Monday after the biopharmaceutical company announced a partnership with Pfizer to develop and commercialize a drug for the treatment of prostate cancer patients. The drug, called Orgovyx, was approved by the FDA on December 18 for the treatment of adult patients with advanced prostate cancer. Myovant is also working on a relugolix combination tablet that could treat patients with endometriosis and uterine fibroids. That tablet is still awaiting FDA approval. "We are thrilled to partner with Pfizer to unlock the full potential of ORGOVYX in advanced prostate cancer and relugolix combination tablet in uterine fibroids and endometriosis, advancing our mission to redefine care for women and for men," said Lynn Seely, Myovant CEO, in an announcement. "This transformative collaboration will significantly strengthen the upcoming launch of ORGOVYX and the potential launches of relugolix combination tablet in women's health, while substantially enhancing our financial position and enabling us to expand our pipeline of potential new medicines." Read more: Wall Street's biggest firms are warning that these 8 things could crash the stock market's party in 2021

Myovant leaps 35% on Pfizer partnership for development of prostate-cancer drug

Shares of Myovant Sciences soared 27% Monday, after its parent Sumitovant Biopharma unveiled an agreement with Pfizer Inc. to jointly develop a treatment for prostate cancer and women's health in a deal worth up to $4.2 billion in upfront and potential milestone payments.

Myovant shares soar 27% on news of Pfizer prostate cancer drug collaboration worth up to $4.2 billion

Myovant Sciences Ltd. (NYSE: MYOV) shares shot up on Monday after the company announced a new collaboration with the pharmaceutical giant Pfizer Inc.

Why This Recently Approved Prostate Cancer Treatment Could Be Huge for Myovant

Myovant Sciences Ltd (NYSE: MYOV) stock is adding about one-fourth of its market capitalization Monday following a licensing deal with Pfizer Inc. (NYSE: PFE). What Happened: Myovant announced a collaboration with Pfizer to develop and commercialize relugolix for oncology indications and women's health in the U.S. and Canada.

Deal With Pfizer Sends Myovant Shares Higher: What Investors Need To Know

The shares of Myovant Sciences Ltd (NYSE:MYOV) are up 27.2% at $29.08 at last check, gapping to record highs, after the biopharmaceutical concern announced a collaboration with Pfizer (PFE) to develop and commercialize cancer treatment relugolix in both the U.S. and Canada.

Biopharmaceutical Stock Surges Thanks to Pfizer Partnership

Myovant and Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and Canada

UPDATE - Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to Develop and Commercialize Relugolix in Oncology and Women's Health

News for Pfizer Stock (PFE)